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Abstract — The combination of modern interventional and pre-
ventive medicine has led to an epidemic of ageing. While this 
phenomenon is a positive consequence of an improved lifestyle 
and achievements in a society, the longer life expectancy is often 
accompanied by decline in quality of life due to musculoskeletal 
pain and disability.
The Aarhus Regenerative Orthopaedics Symposium (AROS) 
2015 was motivated by the need to address regenerative chal-
lenges in an ageing population by engaging clinicians, basic sci-
entists, and engineers. In this position paper, we review our con-
temporary understanding of societal, patient-related, and basic 
science-related challenges in order to provide a reasoned road-
map for the future to deal with this compelling and urgent health-
care problem.
■
The world population is ageing. Many nations are experienc-
ing an epidemic of ageing due to reduced fertility rates and 
longer life expectancy (WHO 2011). Western societies have 
already experienced a major transition in the population age 
distribution, and now the most profound ageing is being seen 
in the developing countries. Currently, China—the country 
with the largest population (1.4 billion)—is transforming into 
an ageing nation with 400 million people over 65 years old 
expected by 2050 (Zeng 2012).
Although a substantially greater percentage of the world’s 
population is living longer, many people are doing so with a 
reduced quality of life due to disability and pain from musculo-
skeletal tissue degeneration, which results in debilitating con-
ditions. The sequelae of the ageing epidemic have thus brought 
into clearer focus the need to: (1) gain a better understanding 
Electronic Supplementum no 363: AROS meeting Århus 2015, Denmark
10181 Foldager D.indd   1 3/9/2017   2:59:20 PM
2 
of the cause of age-related musculoskeletal tissue degenera-
tion; (2) formulate strategies involving changes in lifestyle, 
physiotherapy protocols, and/or therapeutics to ameliorate 
the processes underlying this degeneration; and (3) develop 
regenerative treatments that could apply to ageing individu-
als. Regenerative orthopedics deals with restoring the body’s 
native musculoskeletal tissues following traumatic or degen-
erative damage. Orthopedic surgery has—perhaps somewhat 
inconspicuously—been at the forefront of regenerative treat-
ment strategies dating back to the discovery of the osteoinduc-
tive properties of demineralized bone matrix (DBM) with its 
bone morphogenetic proteins (BMPs) by Marshall R. Urist in 
1965 (Urist 1965), and subsequent purifi cation and character-
ization of BMPs in the late 1980s (Wozney et al. 1988, Luyten 
et al. 1989). This was followed by cell-based treatments such 
as autologous chondrocyte implantation (ACI) in 1994 (Britt-
berg et al. 1994), and more recently the use of mesenchymal 
stem cells (MSCs) for treatment of cartilage lesions (Nejadnik 
et al. 2010, Wong et al. 2013).
The Aarhus Regenerative Orthopaedics Symposium 
(AROS) 2015 involved an interdisciplinary group of basic 
scientists and clinicians working with orthopedic regenera-
tive treatments. The goal was to review our contemporary 
understanding of issues related to orthopedic regeneration in 
an ageing population in order to provide a reasoned roadmap 
for the future to deal with this healthcare problem. A previous 
journal issue of articles collected into a “symposium” in 2004 
addressed the orthopedic challenges to be met in dealing with 
the ageing epidemic (Strauss 2004). AROS was organized to 
bring this problem into a clearer, contemporary light. This 
position paper is accompanied by 4 review papers on selected 
topics related to our current understanding of (1) the underly-
ing causes of age-related musculoskeletal tissue degeneration 
with comments on the most promising targets for the amelio-
ration of the degenerative processes, and (2) the prospects and 
promise of regenerative orthopedics in an ageing population.
Regenerative challenges in the ageing population
What is an older or elderly person? Developed countries have 
generally accepted having reached the age of 65 years as a 
defi nition (WHO 2016). From cellular, physiological, and 
mental standpoints, however, an exact defi nition becomes 
inaccurate and debatable. The exact mechanisms of cellular 
ageing are generally unknown, but they have been shown to 
include telomere shortening, increased DNA methylation, 
heightened oxidative stress and infl ammation, and changes in 
mTOR-regulated autophagy. Some of the underlying mecha-
nisms of cellular ageing for specifi c musculoskeletal tissues 
are discussed in selected review papers in this special issue. 
We have divided the challenges that have been identifi ed into 3 
themes: societal, patient-related, and basic science-related, in 
order to describe the issues and associated challenges. 
Societal challenges
Rising healthcare expenditure has already proven to be an 
important topic on the political agenda, mainly due to the 
demographic shift in age distribution and development of 
new treatments. Furthermore, the lack of proportional rela-
tionships between public health and associated costs calls for 
an increased focus on cost-effectiveness. The use of ACI for 
the treatment of focal cartilage lesions in the knee is a recent 
example of a validated treatment with good long-term clini-
cal follow-up data that is unavailable in many countries due to 
the high cost of in vitro cell expansion (Clar et al. 2005). As 
a consequence, the use of minced autologous cartilage chips 
embedded in fi brin glue has been developed as a potential cost-
effective alternative for some of these patients (Christensen et 
al. 2015). Scientists in regenerative medicine have traditionally 
(and for good reasons) focused on novel and advanced tech-
nologies in the hope of breakthrough discoveries (Toh et al. 
2014). The growing market for off-the-shelf tissue-engineering 
products and banked cells and tissues is driving innovations in 
regenerative orthopedics. However, a more pragmatic approach 
is to include early considerations of the potential cost to the 
end-user, as this dictates the magnitude of clinical use. Hence, 
true scientifi c novelty in the development of regenerative thera-
pies in orthopaedics may be the combination of technology and 
its applicability for translation into societal and clinical use. 
In healthcare expenditure prioritization, a focus on preven-
tion versus disease treatment has shown importance, especially 
in cardiovascular medicine and endocrinology—with several 
successful examples including: statins; anticoagulants; and 
control of blood sugar level through exercise, dietary restric-
tions, and medication.
Patient-related challenges
Outcome measures
Patient-related outcome measures (PROMs) have been used 
for the evaluation of clinical outcomes in orthopedics for 
decades, which today are often included in national reg-
istries. PROMs address general and disease-specifi c well-
being before, during, and after treatment in order not only to 
determine whether a treatment works, but also how it works 
(Greenhalgh et al. 2005). Validation of PROMs is an extensive 
process. Most questions in PROMs are age-neutral, but ques-
tions such as whether you have used a stick or crutch within 
the last 4 weeks may be more important for an 80-year-old 
than for a 15-year-old, compared to, for example, the ques-
tion of whether you are able to squat (Tegner-Lysholm knee-
scoring scale). In the evaluation of regenerative treatments or 
treatments in general, an age-adjusted PROM should weigh 
up the importance of the questions for the individuals, and this 
adjustment is possible if validated with modern item response 
theory (IRT) methods. 
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A Swedish study of 1,099 patients aged 77–100 years showed 
that hypertension, dementia, and heart failure were the most 
prevalent chronic diseases at 38%, 21%, and 18%, respec-
tively, and that 55% had multi-morbidity (Marengoni et al. 
2008). The systemic and local impact of these conditions on 
the effi cacy of any regenerative treatment is unknown, but 
should be considered in future studies. Concomitant pul-
monary dysfunction, cardiovascular disease, and dementia, 
and cognitive impairments of many age-related diseases can 
hinder postoperative rehabilitation, which is an important 
predictor of outcome in many orthopedic surgical treatments 
(Shelbourne and Klotz 2006, Mithoefer et al. 2009, Heyes et 
al. 2015). 
The tissue microenvironment is important for the regen-
erative outcome regardless of approach (reviewed elsewhere: 
Barthes et al. 2014). Many elderly patients have asymptom-
atic low-grade chronic infl ammation that causes environmen-
tal changes at the cellular level, which have been linked to 
increased incidence of several age-related diseases, includ-
ing osteoarthritis (Koenig et al. 1999, Duncan et al. 2003). 
While the effect of infl ammation on tissue regeneration is not 
well understood, its infl uence on regeneration has begun to be 
reported. Of note are recent studies suggesting that cytokines 
involved in infl ammation may provide both anabolic and cata-
bolic stimuli, which in the future may be modulated in favor 
of tissue regeneration (Filbin 2006, Mountziaris and Mikos 
2008).
Polypharmacy
The tissue microenvironment is affected by medication. Even 
when used alone, commonly prescribed drugs such as non-
steroidal anti-infl ammatory drugs (NSAIDs) are controver-
sial regarding their effects on orthopedic procedures. While 
the effects of single drugs on regeneration may be evaluated 
using simple experimental study designs, elderly patients are 
usually taking several drugs on a regular basis. A review by 
Hajjar et al. (2007) showed that more than half of the patients 
aged 65 or more took ≥ 5 medications per day. Another study 
of 236 patients aged 65 or more in an outpatient clinic showed 
that 60% were taking medications with suboptimal indications 
(Lipton et al. 1992). While little is known about drug interac-
tions in polypharmacy and the consequences of these interac-
tions in the specifi c treatments for which they are prescribed, 
even less is known about their effects on the tissue-specifi c 
microenvironment and regeneration. Polypharmacy or even 
the use of single drugs may thus be a signifi cant clinical con-
founder in treatment outcome in this age group. 
External validity of clinical trials
Much effort is often put into ensuring the internal validity of a 
study by providing suffi cient statistical power, minimizing the 
risk of bias, and eliminating potential confounders. In order 
to ensure a statistically signifi cant difference, strict inclusion/
exclusion criteria are often applied. When investigating suc-
cess of regenerative treatments, initial evaluation of effi cacy is 
most often undertaken in a young and otherwise healthy popu-
lation. Engen et al. (2010) showed that only 4% of patients 
with focal cartilage lesions seen in their practice would satisfy 
the inclusion criteria for all randomized controlled trials per-
formed in articular cartilage repair studies. As a consequence, 
patients receiving treatment may not match those enrolled in 
the clinical studies, which ultimately should have been provid-
ing guidance on patient selection for a specifi c treatment. This 
has been shown with chondrocyte transplantation for repair of 
focal cartilage lesions (Foldager et al. 2016). This discrepancy 
in the profi les of patients in clinical trials and in the general 
treatment population, which may refl ect a bias toward early 
commercial or research successes, is a signifi cant limitation to 
the external validity of these trials.
Basic science-related challenges
Development and adaptation of animal models of 
ageing
Because the exact mechanisms of human ageing are poorly 
understood, the use of animal models in ageing and ageing-
related disease studies is important. However, the develop-
ment and validation of animal models of ageing has several 
pitfalls. Such animal models for ageing-related diseases in 
the musculoskeletal system such as osteoporosis, degenera-
tive synovial joint diseases, and intervertebral disc degenera-
tion include: species with spontaneous disease development 
(Bendele and Hulman 1988); surgical interventions for accel-
erated disease progression (Glasson et al. 2007, Bendtsen et 
al. 2011); transgenic mice (Neuhold et al. 2001); and inbred 
senescence-prone mice (Takeda 1999). While certain spe-
cies with spontaneous age-related diseases might essentially 
recapitulate human disease development, the cost and time 
required mean that such studies are practically non-existent 
in the literature. In all other animal models, it is important 
to understand the inherent limitations of each model. For 
example, in models where surgical manipulation leads to joint 
instability in the knee, and needle puncture of the interver-
tebral disc results in degeneration, the outcome is due to an 
acute infl ammatory response and alteration in biomechanics 
followed by a cascade of local physiological/pathological 
changes in an otherwise healthy animal; this is different from 
the chronic ageing-related degenerative processes usually seen 
in humans. Thus, the impact of accumulated cellular damage 
due to ageing (which can infl uence pathogenesis) is unlikely 
to be recapitulated in these healthy, mechanically insulated 
animals—and this fact is widely neglected in animal studies. 
 
The systemic approach—rejuvenation
It is important to recognize that ageing is a systemic event, not 
a local one. In general, regenerative initiatives and therapeu-
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tics for ageing diseases are principally informed by joint- and 
disease-specifi c mechanisms and may therefore be limited in 
effectiveness; this refl ects the diffi culty in dealing with the 
systemic complexity of ageing. As we are confronted with 
an epidemic of ageing, it is time to shift from treating local 
disease to interdisciplinary and combinatorial approaches tar-
geting areas of systemic rejuvenation as a principle for local 
regeneration, or at least facilitation or acceleration of locally 
applied regenerative treatments.
Summary
Age-related musculoskeletal tissue degeneration is a complex 
and complicated problem, which has always been with us. 
Until 60 years ago, the only way for an individual to deal with 
the pain and disability of this condition was “to cope”, and 
simply to take pain medication. The advent of therapeutics 
for the medical management of the disorder (viz. nonsteroidal 
anti-infl ammatory drugs, NSAIDs) and of the surgical treat-
ment in the form of joint replacement, with its immediate pain 
relief for most patients, transformed the lives of many. How-
ever, we now know that long-term administration of NSAIDs 
comes with its own set of problems, and the limitations in the 
longevity of prosthetic joints is such that arthroplasty cannot 
be relied upon to be a stand-alone modality for dealing with 
the ageing epidemic and the extended lives of older individu-
als. While drugs and devices have helped us through the past 
60 years, it will probably be biologics, in an injectable form, 
that will be necessary to help us through the next 60 years 
(Spector and Lim 2016). These therapeutic promises are, how-
ever, based on an understanding of the mechanisms underly-
ing age-related degeneration with attention to pathophysiol-
ogy of the patient as a whole and to the localized diseases. 
This symposium allowed us to compile a contemporary view 
of these important issues to help us develop meaningful strate-
gies to provide a more satisfactory quality of life in the epi-
demic of ageing. 
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